Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase

Cancer Research

Volumn 70, Issue 24, 2010, Pages 10255-10264

  Colombo, Riccardo ^a   Caldarelli, Marina ^a   Mennecozzi, Milena ^a,b   Giorgini, Maria Laura ^a   Sola, Francesco ^a   Cappella, Paolo ^a   Perrera, Claudia ^a   Re Depaolini, Stefania ^a   Rusconi, Luisa ^a   Cucchi, Ulisse ^a   Avanzi, Nilla ^a   Bertrand, Jay Aaron ^a   Bossi, Roberto Tiberio ^a,c   Pesenti, Enrico ^a   Galvani, Arturo ^a   Isacchi, Antonella ^a   Colotta, Francesco ^a   Donati, Daniele ^a   Moll, Jürgen ^a  

^a Nerviano Medical Sciences ^*  (Italy)

^b JOINT RESEARCH CENTRE   (Italy)

^c Tecan Italia Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; [N (2,6 DIETHYLPHENYL) 1 METHYL 8 ([4 [(1 METHYLPIPERIDIN 4 YL)CARBAMOYL] 2 (TRIFLUOROMETHOXY)PHENYL]AMINO) 4,5 DIHYDRO 1H PYRAZOLO[4,3 H]QUINAZOLINE 3 CARBOXAMIDE); ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BUB1 RELATED PROTEIN; BUB3 PROTEIN; DANUSERTIB; MONOPOLAR SPINDLE 1 KINASE; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; NMS P 715; NOCODAZOLE; PACLITAXEL; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN MAD2; STAUROSPORINE; UBIQUITIN; UNCLASSIFIED DRUG;

ANEUPLOIDY; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; CENTROMERE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MITOSIS; MOUSE; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL;

ANEUPLOIDY; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; HCT116 CELLS; HELA CELLS; HUMANS; MICE; MICE, NUDE; MITOSIS; MITOTIC SPINDLE APPARATUS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; QUINAZOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650322902     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2101     Document Type: Article

References (49)

1. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007;8:379-93.
2. Kops GJ. The kinetochore and spindle checkpoint in mammals. Front Biosci 2008;13:3606-20.
3. Kulukian A, Han JS, Cleveland DW. Unattached kinetochores catalyze production of an anaphase inhibitor that requires a Mad2 template to prime Cdc20 for BubR1 binding. Dev Cell 2009;16:105-17.
4. Peters JM. The anaphase promoting complex/cyclosome: a machine designed to destroy. Nat Rev Mol Cell Biol 2006; 7:644-56.
5. Janssen A, Kops GJ, Medema RH. Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A 2009;106:19108-13.
6. Weiss E, Winey M. The Saccharomyces cerevisiae spindle pole body duplication gene MPS1 is part of a mitotic checkpoint. J Cell Biol 1996;132:111-23.
7. Stucke VM, Sillje HH, Arnaud L, Nigg EA. Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication. EMBO J 2002;21:1723-32.
8. Liu ST, Rattner JB, Jablonski SA, Yen TJ. Mapping the assembly pathways that specify formation of the trilaminar kinetochore plates in human cells. J Cell Biol 2006;175:41-53.
9. Tighe A, Staples O, Taylor S. Mps1 kinase activity restrains anaphase during an unperturbed mitosis and targets Mad2 to kinetochores. J Cell Biol 2008;181:893-901.
10. Hogg D, Guidos C, Bailey D, et al. Cell cycle dependent regulation of the protein kinase TTK. Oncogene 1994;9:89-96. (Pubitemid 24020937)
11. Kang J, Chen Y, Zhao Y, Yu H. Autophosphorylation-dependent activation of human Mps1 is required for the spindle checkpoint. Proc Natl Acad Sci USA 2007;104:20232-7.
12. Jelluma N, Brenkman AB, Van Den Broek NJ, et al. Mps1 phosphorylates Borealin to control Aurora B activity and chromosome alignment. Cell 2008;132:233-46.
13. Schmidt M, Budirahardja Y, Klompmaker R, Medema RH. Ablation of the spindle assembly checkpoint by a compound targeting Mps1. EMBO Rep 2005;6:866-72.
14. Kwiatkowski N, Jelluma N, Filippakopoulos P, et al. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function. Nat Chem Biol 2010;6:359-68.
15. Kops GJ, Foltz DR, Cleveland DW. Lethality to human cancer cells through massive chromosome loss by inhibition of the mitotic checkpoint. Proc Natl Acad Sci U S A 2004;101:8699-704.
16. Foijer F, Draviam VM, Sorger PK. Studying chromosome instability in the mouse. Biochim Biophys Acta 2008;1786:73-82.
17. Poss KD, Nechiporuk A, Hillam AM, Johnson SL, Keating MT. Mps1 defines a proximal blastemal proliferative compartment essential for zebrafish fin regeneration. Development 2002;129:5141-9.
18. Cimini D. Merotelic kinetochore orientation, aneuploidy, and cancer. Biochim Biophys Acta 2008;1786:32-40.
19. Satzinger H. Theodor and Marcella Boveri: chromosomes and cytoplasm in heredity and development. Nat Rev Genet 2008;9:231-8.
20. Yuan B, Xu Y, Woo JH, et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 2006;12:405-10.
21. Thykjaer T, Workman C, Kruhoffer M, et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 2001;61:2492-9.
22. Salvatore G, Nappi TC, Salerno P, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res 2007;67:10148-58.
23. Finetti P, Cervera N, Charafe-Jauffret E, et al. Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res 2008;68:767-76.
24. Landi MT, Dracheva T, Rotunno M, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One 2008;3:e1651, 1-8.
25. Mizukami Y, Kono K, Daigo Y, et al. Detection of novel cancer-testis antigen-specific T-cell responses in TIL, regional lymph nodes, and PBL in patients with esophageal squamous cell carcinoma. Cancer Sci 2008;99:1448-54.
26. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006;38:1043-8.
27. de Carcer G, Perez de Castro I, Malumbres M. Targeting cell cycle kinases for cancer therapy. Curr Med Chem 2007;14:969-85.
28. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37.
29. Yang Z, Loncarek J, Khodjakov A, Rieder CL. Extra centrosomes and/ or chromosomes prolong mitosis in human cells. Nat Cell Biol 2008;10:748-51.
30. Wada N, Yoshida A, Miyagi Y, et al. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature. Anticancer Res 2008;28: 139-44.
31. Sotillo R, Hernando E, Diaz-Rodriguez E, et al. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell 2007;11:9-23.
32. Kinoshita-Kikuta E, Aoki Y, Kinoshita E, Koike T. Label-free kinase profiling using phosphate affinity polyacrylamide gel electrophoresis. Mol Cell Proteomics 2007;6:356-66. (Pubitemid 46359522)
33. Stolz A, Vogel C, Schneider V, et al. Pharmacologic abrogation of the mitotic spindle checkpoint by an indolocarbazole discovered by cellular screening efficiently kills cancer cells. Cancer Res 2009;69:3874-83.
34. Kaestner P, Stolz A, Bastians H. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 2009;8:2046-56.
35. Winey M, Goetsch L, Baum P, Byers B. MPS1 and MPS2: novel yeast genes defining distinct steps of spindle pole body duplication. J Cell Biol 1991;114:745-54. (Pubitemid 21909840)
36. Tyler RK, Chu ML, Johnson H, McKenzie EA, Gaskell SJ, Eyers PA. Phosphoregulation of human Mps1 kinase. Biochem J 2009;417:173-81.
37. Fry AM, Yamano H. Under arrest in mitosis: Cdc20 dies twice. Nat Cell Biol 2008;10:1385-7.
38. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008;14:111-22.
39. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
40. Roschke AV, Tonon G, Gehlhaus KS, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634-47.
41. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-17.
42. Holland AJ, Cleveland DW. Boveri revisited: chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 2009;10:478-87.
43. Weaver BA, Cleveland DW. The role of aneuploidy in promoting and suppressing tumors. J Cell Biol 2009;185:935-7.
44. Williams BR, Amon A. Aneuploidy: cancer's fatal flaw? Cancer Res 2009;69:5289-91.
45. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007;11:25-36.
46. Tighe A, Johnson VL, Albertella M, Taylor SS. Aneuploid colon cancer cells have a robust spindle checkpoint. EMBO Rep 2001;2:609-14.
47. Cahill DP, da Costa LT, Carson-Walter EB, Kinzler KW, Vogelstein B, Lengauer C. Characterization of MAD2B and other mitotic spindle checkpoint genes. Genomics 1999;58:181-7.
48. Storchova Z, Breneman A, Cande J, et al. Genome-wide genetic analysis of polyploidy in yeast. Nature 2006;443:541-7.
49. Kwon M, Godinho SA, Chandhok NS, et al. Mechanisms to suppress multipolar divisions in cancer cells with extra centrosomes. Genes Dev 2008;22:2189-203.